Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis

על הניסוי

The general purpose of this trial is to investigate the efficacy and safety of 4 dose strategies of BIBF 1120 treatment for 12 months, compared to placebo in patients with idiopathic pulmonary fibrosis. The primary objective of this study is to demonstrate whether at least one dose strategy is superior to placebo in patients with IPF, in modifying the rate of decline of Forced Vital Capacity (FVC). As a secondary objective, additional parameters will be assessed in order to differentiate between dose strategies on the basis of safety and efficacy

צפו ב-NCT00514683 ב-ClinicalTrials.gov ←

קישורים קשורים